Skip to main content
Log in

Intravenous Milrinone for Cerebral Vasospasm: Here Comes the Sun?

  • Response to Letter To The Editor
  • Published:
Neurocritical Care Aims and scope Submit manuscript

The Original Article was published on 23 November 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Lakhal K, Hivert A, Alexandre P-L, Fresco M, Robert-Edan V, Rodie-Talbere P-A, et al. Intravenous Milrinone for Cerebral Vasospasm in Subarachnoid Hemorrhage: the MILRISPASM controlled before-after study. Neurocrit Care. 2021. https://doi.org/10.1007/s12028-021-01331-z.

    Article  PubMed  Google Scholar 

  2. Mahajan C, Shukla R, Kapoor I, Prabhakar H. Intravenous milrinone for cerebral vasospasm in subarachnoid hemorrhage. Neurocrit Care (in press)

  3. Velly LJ, Bilotta F, Fabregas N, Soehle M, Bruder NJ, Nathanson MH. Anaesthetic and ICU management of aneurysmal subarachnoid haemorrhage: a survey of European practice. Eur J Anaesthesiol. 2015;32:168–76.

    CAS  PubMed  Google Scholar 

  4. Mastantuono J-M, Combescure C, Elia N, Tramèr MR, Lysakowski C. Transcranial Doppler in the diagnosis of cerebral vasospasm: an updated meta-analysis. Crit Care Med. 2018;46(10):1665–72.

    Article  Google Scholar 

  5. Diringer MN, Bleck TP, Claude Hemphill J, Menon D, Shutter L, Vespa P, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15:211–40.

    Article  Google Scholar 

Download references

Funding

No funding was required for this study.

Author information

Authors and Affiliations

Authors

Contributions

Authorship requirements have been met, and the final manuscript was approved by all authors.

Corresponding author

Correspondence to Karim Lakhal.

Ethics declarations

Conflict of interest

Karim Lakhal has no conflict of interest in connection with the work submitted. In addition, KL received, during the past 3 years, congress registration fees from Sanofi Aventis (once in 2018) and travel fees from MSD France (once in 2017), Gilead Sciences (once in 2017), Pfizer (three times, in 2019, 2020, and 2021), and Advanz Pharma (twice in 2020 and once in 2021). Vincent Robert-Edan has no conflict of interest in connection with the work submitted. In addition, VRE received, during the past 3 years, travel fees from Pfizer (once in 2020). None of the other authors have any financial or nonfinancial competing interests in connection with this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a response to a letter to the editor available at https://link.springer.com/article/10.1007/s12028-021-01392-0.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lakhal, K., Robert-Edan, V., Rodie-Talbere, PA. et al. Intravenous Milrinone for Cerebral Vasospasm: Here Comes the Sun?. Neurocrit Care 36, 329–330 (2022). https://doi.org/10.1007/s12028-021-01392-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-021-01392-0

Navigation